Behind Gene Editing’s Big Moment with Sickle-Cell Treatment | WSJ

The U.S. has approved the world’s first medicine to treat sickle-cell disease. Executives from the companies that developed the gene-edited treatment-Crispr Therapeutics and Vertex Pharmaceuticals-discuss the breakthrough's potential and risks.
#Biotech #Healthcare #WSJ

[@militiamc]

Disparities is woke interviewers' new favorite word. It took 70 years for science to get to this point. Disparities has nothing to do with it. How can you talk about disparities slowing access to a a $2M a dose drug??? The drug is not accessible even now at that price.

[@danteberry6047]

First gene editing program ironically is for “Black” people……

[@mattyfatstaxs]

Not the first, roctavian and others have happened before.
But the best and most transformative therapy to date ❤

[@danteberry6047]

@@mattyfatstaxs that’s what they say

[@mattyfatstaxs]

@@danteberry6047hahaha I like it.
I make the most money in stocks by not trusting what a company says so I get the sentiment.
But monthly pain crises and transfusions are a real thing, stopping those is an easy thing to track.
There are patient videos out there too on this.
Treatment isn’t for everyone, but people perish from a lack of knowledge 😢😢

[@zaralot]

Kindof an annoying interviewer. But exciting technology that will provide cures for many rare and common diseases over the next 10 years.

[@massimofulfaro529]

Great companies and great leadership.. I can’t think of any better way to invest your savings .. I feel good every time I buy a share of these 2 jewels.. go vertex go crispr 🎉 human intelligence at the service of the human being health enhancement ❤ it.